Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
17
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(18 citation statements)
references
References 39 publications
1
17
0
Order By: Relevance
“…Low doses of cucurbitacin B or methotrexate cannot inhibit tumor growth in osteosarcoma xenograft mice, however when combined together, they synergistically inhibit tumor growth [498]. The combination therapy of cucurbitacin B and curcumin enhances apoptosis and reverses MDR in human hepatocellular carcinoma Bel-7402/5-Fu cells [499]. Recently, cucurbitacin B is suggested to be a potential candidate when it is applied with withanone, this combination can enhance cytotoxicity in human NSCLC A549 cells, and inhibit tumor growth and metastasis in A549 xenograft mice [500].…”
Section: Cucurbitacinsmentioning
confidence: 99%
“…Low doses of cucurbitacin B or methotrexate cannot inhibit tumor growth in osteosarcoma xenograft mice, however when combined together, they synergistically inhibit tumor growth [498]. The combination therapy of cucurbitacin B and curcumin enhances apoptosis and reverses MDR in human hepatocellular carcinoma Bel-7402/5-Fu cells [499]. Recently, cucurbitacin B is suggested to be a potential candidate when it is applied with withanone, this combination can enhance cytotoxicity in human NSCLC A549 cells, and inhibit tumor growth and metastasis in A549 xenograft mice [500].…”
Section: Cucurbitacinsmentioning
confidence: 99%
“…Cucurbitacin is divided into 12 categories based on different chemical structures. Among them, cucurbitacin B is the most abundant in the family, and has extensive pharmacological activities such as hepatoprotective, antiviral, antibacterial, anti-inflammatory, anti-cancer, etc., [10][11][12][13][14][15][16] However, study on cucurbitacin B about its regulation and mitigation on sepsis-associated AKI and inflammatory response is still blank. Therefore, by adopting caecal ligation puncture to establish the mouse model of sepsis-associated AKI for observing the contents of Cre, BUN, TNF-a and IL-6 in the blood at different time after operation on mice, calculating the organ coefficient after kidney weighing, and observing the pathological changes of renal tissue by HE staining, this study aimed to investigate the mechanism of cucurbitacin B on sepsis-associated AKI and evaluate its preventive and therapeutic effect on sepsis-associated AKI, thus finding a new effective method for clinical treatment of sepsis-associated AKI.…”
Section: Prefacementioning
confidence: 99%
“…In order to reduce the side effects and enhance the efficacy of treatment, traditional Chinese medicine (TCM) prescriptions of synergistic combinations of different herbs have emerged as an alternative strategy for cancer therapy. The combination of cucurbitacin B (Cu B) with another appropriate drug, for example curcumin, can decrease the dosage of Cu B, resulting in reduced toxicity and fewer side effects (2). Our previous study found that Cu B synergistically eliminated the resistance of Burkitt's lymphoma Ramos cells to apoptosis via arsenic trioxide through inhibiting the phosphorylation of signal transducer and activator of transcription 3 (3).…”
Section: Introductionmentioning
confidence: 99%